Shares of Compugen Ltd. (NASDAQ:CGEN) were up 6% during mid-day trading on Friday . The company traded as high as $7.48 and last traded at $7.47, with a volume of 314,439 shares traded. The stock had previously closed at $7.05.

A number of analysts recently issued reports on CGEN shares. Zacks Investment Research upgraded shares of Compugen from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd. FBR & Co restated a “buy” rating on shares of Compugen in a research report on Wednesday, June 22nd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $10.25.

The firm’s market cap is $377.23 million. The firm’s 50-day moving average is $6.77 and its 200-day moving average is $6.39.

Compugen (NASDAQ:CGEN) last released its earnings results on Tuesday, August 2nd. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04. Equities research analysts forecast that Compugen Ltd. will post ($0.56) earnings per share for the current fiscal year.

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.